Ipamorelin & CJC-1295, Explained
How the most commonly paired growth hormone secretagogues work, what the protocols look like, and what to watch for
title: "Ipamorelin & CJC-1295, Explained" dek: "How the most commonly paired growth hormone secretagogues work, what the protocols look like, and what to watch for" slug: "ipamorelin-cjc-1295" date: "2026-04-14" tags: ["peptides", "education"]
If you've spent any time in longevity medicine circles, you've likely encountered this combination: ipamorelin paired with CJC-1295 (specifically the version without DAC — Drug Affinity Complex). It's one of the most widely used peptide protocols among physicians working in anti-aging and functional medicine, and it has a cleaner safety profile than most of the other compounds in its category.
Understanding why requires understanding how they work — and why they're so often used together rather than separately.
The Problem They're Addressing
Growth hormone (GH) naturally declines with age. After the peak years of adolescence, secretion drops by roughly 15 percent per decade. By age 55, natural daily GH output may be as low as one-sixth of what it was at puberty, according to clinical data reviewed by Dr. William Seeds of the SSRP Institute. IGF-1 — the downstream mediator of most of GH's tissue effects — follows a similar trajectory.
This decline tracks with a cluster of changes that become familiar in middle age: reduced muscle mass and recovery, increased visceral fat, disrupted sleep architecture, slower connective tissue repair. Not all of those changes are caused purely by GH decline — aging is multifactorial — but the correlation is consistent.
The instinct to simply inject synthetic human growth hormone (HGH) is understandable but flawed. Direct HGH injection bypasses the body's feedback loops. The pituitary no longer needs to produce its own; over time, the gland's responsiveness can diminish. There's also the issue of supraphysiologic levels — more GH than the body would ever naturally produce, sustained for hours rather than released in pulses. That pattern is associated with increased cancer risk, insulin resistance, and other downstream problems. The secretagogue approach is designed specifically to avoid this by working with the body's existing regulatory architecture rather than overriding it.
How Each Peptide Works
CJC-1295 (Mod-GRF 1-29): The GHRH Analog
Your hypothalamus naturally releases growth hormone-releasing hormone (GHRH) in pulses — roughly three to eight times per day. GHRH travels to the pituitary's somatotroph cells, which then release a pulse of GH in response.
CJC-1295 without DAC is a modified version of the first 29 amino acids of GHRH. It binds to the same receptor, producing the same downstream signal. Its half-life is approximately 30 minutes, which means it generates a defined pulse and clears — mimicking the natural pattern — rather than causing sustained, continuous stimulation.
The version with DAC (Drug Affinity Complex) has a much longer half-life — up to eight days — because it's engineered to bind to albumin in the bloodstream and release slowly. This creates continuous GH elevation rather than pulsatile release, which is generally considered less desirable from a physiologic standpoint. This is why most protocols specify "no DAC" — the pulsatile pattern is the goal.
Ipamorelin: The Ghrelin Mimetic
Ipamorelin works through a completely separate receptor. It's a synthetic agonist of the growth hormone secretagogue receptor (GHSR-1a) — the same receptor that binds ghrelin, the hunger hormone produced mainly in the stomach.
Ghrelin has GH-releasing activity; ipamorelin mimics that activity with high selectivity for the GH pathway. This selectivity is a key feature. Earlier GHRPs — GHRP-2 and GHRP-6 — stimulate GH release effectively but also raise cortisol, prolactin, and other hormones as side effects. Ipamorelin is considered the most selective of the GHRPs: it stimulates GH release without meaningfully affecting ACTH, cortisol, prolactin, FSH, LH, TSH, or thyroid hormones, as described in clinical pharmacology literature on GHRP selectivity.
Its half-life is approximately two hours, which is longer than CJC-1295 but still short enough to produce a defined pulse.
Why They're Paired
CJC-1295 and ipamorelin stimulate GH through different receptor pathways. When used together, their effects are synergistic rather than merely additive — the combination produces approximately five times the GH release of either compound alone, per pharmacological literature reviewed by Dr. Seeds and SSRP Institute researchers. This synergy means lower doses of each compound can achieve a meaningful effect, which is both more economical and — in principle — a more physiologic response pattern.
Dosing Ranges Seen in Clinical Practice
Dosing information here is drawn from clinical education materials reviewed by the Nexus research base, including observational data compiled by Dr. Seeds and SSRP Institute fellows, as well as protocols documented in longevity medicine practice. These represent ranges observed in clinical and research contexts, not prescriptions or personal recommendations.
Standard longevity/wellness protocol:
- Ipamorelin: 100–200 mcg per injection
- CJC-1295 (no DAC / Mod-GRF 1-29): 100–200 mcg per injection
- Frequency: once daily
- Timing: fasted, at bedtime — aligning the dose with the body's natural overnight GH peak
- Cycle length: 8–12 weeks on, then a break period to allow pituitary receptor rest
More conservative starting point (referenced in clinical practice):
- 100 mcg of each compound
- Five days per week (with weekend breaks)
- Injected together, subcutaneously into belly fat
Intensive protocols — up to 600 mcg of each, three times daily — are referenced in the observational literature as being used for short-term clinical applications like sarcopenia treatment or post-illness recovery. These are not considered longevity approaches and fall well outside routine wellness use.
The reasoning behind cycling (rather than continuous use) is that sustained receptor stimulation can reduce receptor sensitivity over time — the pituitary's GHRPs receptors need rest intervals to maintain responsiveness. Eight to twelve weeks on, followed by a bridge period of several weeks, is the pattern most commonly referenced in clinical settings.
Timing and Administration
Timing matters because GH naturally peaks during sleep, and the pituitary is most responsive when insulin levels are low. Eating a large meal before injection raises insulin, which blunts the GH response. The standard recommendation across all sources is to inject in a fasted state: at least two hours after eating, and ideally 30 minutes before a small late-night snack or simply at bedtime.
Morning fasted dosing is an alternative for those who find bedtime injections impractical. Evening is generally preferred because of the alignment with natural GH release cycles.
Administration is subcutaneous — a small amount of belly fat is the standard site, using an insulin-type syringe (29–30 gauge, half-inch needle). The injections are shallow and, once technique is established, relatively painless.
Who Is Likely to Benefit
The individuals who appear to have the most to gain from GH secretagogue protocols are those with documented, clinically meaningful declines in GH output. In practical terms, this typically means:
- Adults over 50 with lower IGF-1 on lab testing, combined with symptoms like poor sleep, slow recovery, declining lean mass, or increased visceral adiposity
- People for whom lifestyle optimization (sleep quality, resistance training, adequate protein) has been pursued and plateaued
- Those under physician supervision who have been screened for contraindications
The observational literature notes that "the natural decline of GH becomes increasingly apparent after age 50" and that the combination protocol supports "metabolic balance, improved sleep, tissue recovery, and overall longevity" — though it's important to note that these claims are observational in nature, not derived from randomized controlled trials.
GH secretagogues appear to produce their most meaningful effects in people who have the most room to gain — those with low baseline GH/IGF-1. In people with normal-to-high GH output (generally, younger adults), the incremental benefit is less clear.
Who Should Not Use These Compounds
Active cancer or cancer history: Any intervention that elevates IGF-1 warrants serious discussion with an oncologist for people with cancer histories. IGF-1 has mitogenic (cell-growth-stimulating) properties; this is a genuine biological risk worth taking seriously.
Diabetes and insulin resistance: Elevated GH can worsen insulin sensitivity in some people. Blood glucose monitoring is prudent for anyone with metabolic concerns.
Pregnancy and breastfeeding: These compounds have not been studied in pregnancy. Avoid.
Active autoimmune disease or hypersensitivity: Ipamorelin has anecdotal reports of allergic reactions. A very low starting dose (as low as 50 mcg) and a waiting period is recommended before full-dose use.
Pituitary or hypothalamic pathology: Anyone with a pituitary tumor, Cushing's disease, or acromegaly should not use these compounds without careful specialist oversight.
Monitoring
Physicians prescribing these compounds typically track:
- IGF-1 levels (to confirm the protocol is working and to screen for excessive elevation)
- Fasting glucose and HbA1c (insulin sensitivity)
- Resting signs of fluid retention (mild edema can occur)
IGF-1 is considered the most useful surrogate marker for GH axis activity — a level running significantly above age-appropriate ranges would be a signal to reduce dose or pause.
Safety & Disclaimer
This article is educational and does not constitute medical advice. Ipamorelin and CJC-1295 are not FDA-approved for the general wellness applications described here. In the United States, they are available through compounding pharmacies under physician supervision, or through research chemical suppliers in a legal but less regulated context. These are not equivalent in terms of quality assurance or safety accountability.
If you are 50 or older, managing a chronic condition, taking prescription medications, or have any personal or family history of cancer or hormone-sensitive conditions, please discuss these topics with your physician before pursuing any protocol. A physician who is familiar with peptide pharmacology can evaluate your specific situation, order appropriate baseline labs, and guide monitoring in a way that general information cannot.
This is an area where personalized medicine genuinely matters — what's appropriate for one person may be contraindicated for another.